[go: up one dir, main page]

ES2168110T3 - Derivados de oxima sustituida utiles como inhibidores de las fosfoesterasas de tipo iv. - Google Patents

Derivados de oxima sustituida utiles como inhibidores de las fosfoesterasas de tipo iv.

Info

Publication number
ES2168110T3
ES2168110T3 ES95922648T ES95922648T ES2168110T3 ES 2168110 T3 ES2168110 T3 ES 2168110T3 ES 95922648 T ES95922648 T ES 95922648T ES 95922648 T ES95922648 T ES 95922648T ES 2168110 T3 ES2168110 T3 ES 2168110T3
Authority
ES
Spain
Prior art keywords
sup
group
rent
optionally replaced
sub
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95922648T
Other languages
English (en)
Inventor
John Clifford Head
Graham John Warrelow
Rikki Peter Alexander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Application granted granted Critical
Publication of ES2168110T3 publication Critical patent/ES2168110T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES DE FORMULA (1) EN DONDE =W- ES (1) =C(()Y())- DONDE Y ES UN ATOMO DE HALOGENO, O UN GRUPO ALQUILO O GRUPO -XR{SUP,A} DONDE X ES -O-, -S(()O()){SUB,M}- [DONDE M ES CERO O UN ENTERO DE VALOR (1) O (2)], O -N(()R{SUP,B}())- [DONDE R{SUP,B} ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO OPCIONALMENTE SUSTITUIDO] Y R{SUP,A} ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO OPCIONALMENTE SUSTITUIDO O, (2) =N-; L ES UN XR, [DONDE R ES UN GRUPO ALQUILO, ALQUENILO, CICLOALQUILO O CICLOALQUENILO OPCIONALMENTE SUSTITUIDO], C(()R{SUP,5}())=C(()R{SUP,1}())(()R{SUP,2}()) O UN GRUPO [[]CH(()R{SUP,5}())[]]{SUB,N}CH(()R{SUP,1}())(()R{SUP,2}()) DONDE R{SUP,5} ES UN ATOMO DE HIDROGENO O DE FLUOR O UN GRUPO DE METILO, Y R{SUP,1} Y R{SUP,2}, QUE PUEDEN SER EL MISMO O DIFERENTES, ES CADA UNO UN ATOMO DE HIDROGENO O DE FLUOR O UN GRUPO ALQUILO, ALQUENILO, ALQUINILO, ALCOXI, ALQUILTIO OPCIONALMENTE SUSTITUIDOS, -CO{SUB,2}R{SUP,6}, [DONDE R{SUP,6} ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO, ARALQUILO O ARILO OPCIONALMENTE SUSTITUIDO], -CONR{SUP,7}R{SUP,8} [DONDE R{SUP,7} Y R{SUP,8}, QUE PUEDEN SER EL MISMO O DIFERENTES SON COMO SE DEFINIAN PARA R{SUP,6}], -CSNR{SUP,7}R{SUP,8}, -CN O -NO{SUB,2}, O R{SUP,1} Y R{SUP,2} JUNTO CON EL ATOMO C AL QUE ESTAN UNIDOS ESTAN ENLAZADOS PARA FORMAR UN GRUPO CICLOALQUILO O CICLOALQUENILO OPCIONALMENTE SUSTITUIDO Y N ES CERO O EL ENTERO (1); AR ES UN GRUPO -(()CH{SUB,2}()){SUB,N}-Z-AR'' DONDE AR'' ES UN GRUPO HETEROARILO MONOCICLICO O BICICLICO OPCIONALMENTE SUSTITUIDO Y Z ES UN ENLACE, UN ATOMO -O-, -S- O UN GRUPO N((R{SUP,B}())- Y N ES CERO O EL ENTERO 1, 2, 3 O 4; R{SUP,3} ES UN ATOMO DE HIDROGENO, O UN GRUPO ALQUILO, ALQUENILO, ALQUINILO, -C(()O())R{SUP,4} (DONDE R{SUP,4} ES UN GRUPO AMINO, ALQUILAMINO, ARILAMINO, ALCOXI, ARILOXI O UN GRUPO ALQUILO OPCIONALMENTE SUSTITUIDO) O -C(()S())R{SUP,4} OPCIONALMENTE SUSTITUIDO; Y LAS SALES, SOLVATOS, HIDRATOS, PROFARMACOS Y N-OXIDOS DE LOS MISMOS. COMPOSICIONES DE ACUERDO CON LA INVENCION SON INHIBIDORESDE FOSFODIESTERASA TIPO IV Y SON UTILES EN LA PROFILAXIS Y TRATAMIENTO DE ENFERMEDADES COMO ASMA DONDE HAY PRESENTE RESPUESTAS INFLAMATORIAS O ESPASMOS MUSCULARES NO DESEADOS.
ES95922648T 1994-06-23 1995-06-23 Derivados de oxima sustituida utiles como inhibidores de las fosfoesterasas de tipo iv. Expired - Lifetime ES2168110T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9412672A GB9412672D0 (en) 1994-06-23 1994-06-23 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2168110T3 true ES2168110T3 (es) 2002-06-01

Family

ID=10757248

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95922648T Expired - Lifetime ES2168110T3 (es) 1994-06-23 1995-06-23 Derivados de oxima sustituida utiles como inhibidores de las fosfoesterasas de tipo iv.

Country Status (7)

Country Link
US (1) US5693659A (es)
EP (1) EP0766673B1 (es)
AU (1) AU2747395A (es)
DE (1) DE69525254T2 (es)
ES (1) ES2168110T3 (es)
GB (1) GB9412672D0 (es)
WO (1) WO1996000215A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
ATE260911T1 (de) * 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
TW375612B (en) * 1995-04-06 1999-12-01 Janssen Pharmaceutica Nv 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
US5981549A (en) * 1997-02-14 1999-11-09 Synapse Pharmaceutical International Method for controlling or alleviating the symptoms of respiratory disease and allergies
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6639077B2 (en) 2000-03-23 2003-10-28 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
AU2001259758A1 (en) 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
JP2003534328A (ja) 2000-05-25 2003-11-18 メルク フロスト カナダ アンド カンパニー フルオロアルコキシ置換ベンズアミドジクロロピリジニルｎ−オキシドｐｄｅ４阻害剤
US6740666B2 (en) 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
DE10064997A1 (de) 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US7205320B2 (en) * 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
CN1520313A (zh) 2001-05-23 2004-08-11 ������ҩ��ʽ���� 一种加速骨折愈合的组合物
ES2427930T3 (es) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
WO2002094823A1 (en) 2001-05-24 2002-11-28 Merck Frosst Canada & Co. 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
IL159120A0 (en) * 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
RU2368604C2 (ru) 2002-07-19 2009-09-27 Мемори Фармасьютиклз Корпорейшн Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина
CA2492911A1 (en) * 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
KR20050075430A (ko) 2002-11-19 2005-07-20 메모리 파마슈티칼스 코포레이션 포스포디에스테라제 4 억제제
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
CA2533636A1 (en) * 2003-07-31 2005-02-10 Altana Pharma Ag Novel 6-phenylphenanthridines
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
KR100879423B1 (ko) 2004-12-02 2009-01-19 (주)아모레퍼시픽 Ｔｎｆ-알파의 생산을 저해하는 2-사이클로펜텐-1-온 옥심유도체
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103819408B (zh) * 2014-03-13 2015-08-05 山东理工大学 硝基咪唑衍生物及其制备方法和用途
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257272B1 (es) * 1974-01-15 1978-08-25 Pharmascience Labo
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
SU888821A3 (ru) * 1976-12-03 1981-12-07 Шеринг Аг (Инофирма) Способ получени 5-(замещенный фенил)-оксазолидинонов или их серусодержащих аналогов
DE2962383D1 (en) * 1978-06-15 1982-05-06 Ici Plc Anti-inflammatory 1-phenyl-2-aminoethanol derivatives, pharmaceutical compositions thereof for topical use, and processes for their manufacture
ES2087056T3 (es) * 1986-01-13 1996-07-16 American Cyanamid Co 2-pirimidinaminas sustituidas en las posiciones 4, 5 y 6.
US4788195A (en) * 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
US4876252A (en) * 1986-01-13 1989-10-24 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
WO1987006576A1 (en) * 1986-04-29 1987-11-05 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
US5128358A (en) * 1988-01-19 1992-07-07 Pfizer Inc. Aryl substituted nitrogen heterocyclic antidepressants
US4792561A (en) * 1986-05-29 1988-12-20 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors
US4921862A (en) * 1986-05-29 1990-05-01 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US5274002A (en) * 1987-04-14 1993-12-28 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
EP0295210B1 (de) * 1987-06-11 1993-08-04 Ciba-Geigy Ag Mikrobizide
US4966622A (en) * 1988-04-12 1990-10-30 Ciba-Geigy Corporation N-phenyl-N-pyrimidin-2-ylureas
US4897396A (en) * 1988-06-03 1990-01-30 Ciba-Geigy Corporation 2-phenylamino pyrimidine derivatives and their uses as microbicides
ATE124401T1 (de) * 1989-04-17 1995-07-15 Byk Gulden Lomberg Chem Fab Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel.
JPH0377923A (ja) * 1989-08-18 1991-04-03 Sekisui Chem Co Ltd 有機非線形光学材料
JPH075572B2 (ja) * 1989-08-18 1995-01-25 積水化学工業株式会社 ２―［２―（２―ヒドロキシフェニル）ビニルピラジンおよびその製造法
DE4003919A1 (de) * 1990-02-09 1991-08-14 Basf Ag Heteroarylalkene, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
WO1991016892A1 (en) * 1990-04-27 1991-11-14 Rorer International (Holdings), Inc. Styryl compounds which inhibit egf receptor protein tyrosine kinase
IL98764A0 (en) * 1990-07-10 1992-07-15 Smithkline Beecham Corp Oxamides
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
WO1992006085A1 (en) * 1990-09-28 1992-04-16 Smith Kline & French Laboratories Limited Phenylpyridinol derivatives as medicaments
EP0553174B1 (de) * 1990-10-16 1998-07-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Arylpyridazinone
AU9030691A (en) * 1990-11-06 1992-05-26 Smithkline Beecham Corporation Imidazolidinone compounds
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
EP0581805A1 (de) * 1991-04-26 1994-02-09 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridazine
US5191084A (en) * 1991-05-01 1993-03-02 American Home Products Corporation Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
EP0540165A1 (en) * 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
US5326898A (en) * 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
DE69328778T2 (de) * 1992-04-02 2000-11-23 Smithkline Beecham Corp., Philadelphia Verbindungen für die behandlung von entzündlichen erkrankungen und zur hemmung der produktion von tumornekrosefaktor
TW225528B (es) * 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9212693D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
ATE150447T1 (de) * 1992-06-15 1997-04-15 Celltech Therapeutics Ltd Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren
MX9304571A (es) * 1992-07-28 1994-05-31 Rhone Poulenc Rorer Ltd Compuestos fanilicos ligados a un arilo o heteroarilo mediante un radical alifatico o un atomo heterogeneo que contiene un grupo eslabonador.
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
EP0672031B1 (en) * 1992-12-02 2003-03-12 Pfizer Inc. Catechol diethers as selective pde iv inhibitors
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
TW263495B (es) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
TW266206B (es) * 1993-04-28 1995-12-21 Takeda Pharm Industry Co Ltd
DE4328385A1 (de) * 1993-08-24 1995-03-02 Bayer Ag 2-Oximino-2-pyridyl-essigsäurederivate
WO1995009847A1 (en) * 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
ATE325113T1 (de) * 1993-10-01 2006-06-15 Novartis Pharma Gmbh Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
DK0672041T3 (da) * 1993-10-01 2002-02-25 Novartis Ag Farmakologisk aktive pyridinderivater og fremgangsmåder til fremstilling deraf
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process

Also Published As

Publication number Publication date
GB9412672D0 (en) 1994-08-10
AU2747395A (en) 1996-01-19
DE69525254T2 (de) 2002-12-19
WO1996000215A1 (en) 1996-01-04
EP0766673A1 (en) 1997-04-09
DE69525254D1 (de) 2002-03-14
US5693659A (en) 1997-12-02
EP0766673B1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
ES2168110T3 (es) Derivados de oxima sustituida utiles como inhibidores de las fosfoesterasas de tipo iv.
PE14895A1 (es) Metodo para preparar y seleccionar compuestos no peptidos con utilidad farmaceutica a partir de una biblioteca universal estructuralmente diversa
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
EA200000391A1 (ru) Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов
ES2176708T3 (es) Composiciones detergentes.
ES2084944T3 (es) Amidas terapeuticas.
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
CO4560551A1 (es) Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion
ATE266013T1 (de) 1-phenyl-4-benzylpiperazine: spezifische liganden für den dopamin rezeptor (d4)
ES2142030T3 (es) Nuevos compuestos espiro-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ATE57919T1 (de) Triazinderivate, verfahren zur herstellung der derivate und die derivate als wirksamen bestandteil enthaltende herbizide.
ATE243209T1 (de) Tetrahydro gamma-carboline
DE69014064D1 (de) Benzopyranon-beta-D-thioxyloside, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung.
PT870761E (pt) Derivados de tiocolchicina com actividades anti-inflamatoria e relaxante muscular
ES2127862T3 (es) Preparados cosmeticos que contienen 1-hidroxi-2-piridonas como agentes anticaspa y desodorantes.
DE69824195D1 (de) Dipyridoimidazolderivate zur behandlung von störungen des zentralen nervensystems
ES2104370T3 (es) Derivados de (arilalquilaminobencil)aminopropionamidas sustituidas, su preparacion y utilizacion.
UA41329C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, похідні 3-фенілсульфоніл-3,7-діазабіцикло[3,3,1]нонану та лікарський засіб для лікування аритмії
ATE219486T1 (de) Trizyklische indol-2-carbonsäure derivate als selektive nmda rezeptor antagonisten
ES2169909T3 (es) 5-hidroximetil-2-aminotetralinas como agentes cardiovasculares.
BR9707335A (pt) Derivados de 2,3-benzodiazepina sua preparação e emprego como medicamento
ES2081447T3 (es) Sulfonil-fenil-beta-d-tioxilosidos, su procedimiento de preparacion y su empleo en terapeutica.
ES2151612T3 (es) Derivados de 19-nor-progesterona puenteados en 14alfa,17alfa-c2.
ATE144766T1 (de) Nichtionische jodhaltige röntgenstrahlenkontrastmittel, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 766673

Country of ref document: ES